Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Thoracic Malignancies
•
Medical Oncology
•
EGFR+
Does anyone have experience obtaining sunvozertinib in the second line setting for patients with EGFR exon 20 insertion mutations?
Related Questions
How do you approach treatment selection among novel bispecific antibodies and ADCs for patients with EGFR+ NSCLC previously treated with 3rd generation EGFR inhibitors?
Would you consider omitting concurrent chemoradiation for a patient with stage III EGFR-mutant NSCLC and initiating treatment with osimertinib instead?
Would you add immunotherapy to chemotherapy for a patient with metastatic NSCLC, an atypical EGFR mutation, and PD-L1 ≥50% who has progressed on osimertinib?
What is your preferred treatment option after tarlatamab for patients with ES-SCLC?
How would you approach adjuvant therapy for patients with mucinous lung adenocarcinoma with an intestinal phenotype?
For patients with stage I NSCLC, do you use RiskReveal, and if so, how do you use it to guide treatment?
When do you recommend incorporating HER2 testing into the diagnostic pathway for tumor types where HER2 overexpression is not commonly assessed?
When, if at all, do you utilize neoadjuvant chemotherapy alone for resectable, Stage II NSCLC with mutations such as EGFR or ALK?
Will you offer lurbinectedin with atezolizumab for patients with ES-SCLC during maintenance if they had brain metastases at baseline?
In patients with IV NSCLC and EGFR mutation, is there a cutoff on the % of allele frequency that is considered to be too low to be actionable?
